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RegressionDiabetes and arterial hypertension continue to be the main causes of chronic renal failure in 2010, with a
rising prevalence in part due to the worldwide obesity epidemic. Proteinuria is a main feature of chronic
renal disease and mediated by defects in the glomerular ﬁltration barrier and is as a good predictor of
cardiovascular events. Indeed, chronic renal disease due to glomerulosclerosis is one of the important risk
factors for the development of coronary artery disease and stroke. Glomerulosclerosis develops in response
to inﬂammatory activation and increased growth factor production. Preclinical and ﬁrst preliminary clinical
studies provide strong evidence that endogenous endothelin-1 (ET-1), a 21-amino-acid peptide with strong
growth-promoting and vasoconstricting properties, plays a central role in the pathogenesis of proteinuria
and glomerulosclerosis via activation of its ETA subtype receptor involving podocyte injury. These studies
have not only shown that endothelin participates in the disease processes of hypertension and
glomerulosclerosis but also that features of chronic renal disease such as proteinuria and glomerulosclerosis
are reversible processes. Remarkably, the protective effects of endothelin receptors antagonists (ERAs) are
present even on top of concomitant treatments with inhibitors of the renin–angiotensin system. This review
discusses current evidence for a role of endothelin for proteinuric renal disease and podocyte injury in
diabetes and arterial hypertension and reviews the current status of endothelin receptor antagonists as a
potential new treatment option in renal medicine.ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Discovery and physiological relevance of endothelin
Robert F. Furchgott (1916–2009) [1]made the seminal observation
30 years ago that vascular endothelial cells modulate vascular tone by
releasing vasoactive factors [2]. Furchgott himself [3], as well as
Ignarro et al. [4], later identiﬁed this factor as nitric oxide (NO).
Subsequently, research in the early 1980s was concentrated on
identifying new vasoactive molecules [1]. Already shortly after the
initial discovery, it became clear that endothelial cells also release
vasoconstrictor substances [5]. Work of several laboratories from the
mid-1980s identiﬁed a potent vasoconstrictor substance released into
the supernatant of endothelial cells [6,7]. The race in search of the
identity and the sequence of the gene encoding for a 21-amino-acid
peptide was on and a consortium of several Japanese laboratories led
by Tomoh Masaki [8,9] identiﬁed the peptide named endothelin-1,
whichwas published inNature byMasashi Yanagisawa and colleagues
in 1988 [10].
Endothelin-1 is the biologically predominant isoform of the endothe-
lin peptide family, which also includes endothelin-2 and endothelin-3,as well as 31- and 32-amino-acid isoforms of the peptide [11,12].
Endothelin binds to two receptors (ETA and ETB) that were identiﬁed
shortly after discovery of the ligands [11,13]. ETA receptors primarily
have vasoconstrictor and growth-promoting functions, whereas ETB
receptors mediate mainly vasodilation and inhibition of growth and
inﬂammation via nitric oxide and prostacyclin [11]. ETB receptors can
therefore be regarded largely as “endogenous antagonistic receptors”
counteracting the effects of the ETA receptor.
In humans, endothelin represents the most potent and long-
lasting vasoconstrictor known and is about 100 times more potent
than noradrenaline [12]. Endothelins (ETs) can be considered
ubiquitously expressed stress-responsive regulators of cell function
that act in a paracrine and autocrine fashion [13]. Endothelins exert a
number of physiological functions, including embryonic development
[14] and intestinal growth as well as natriuresis, the latter of which is
maintained via activation of the ETB receptor [13,15], in the renal
medulla. In principal cells of the collecting duct, activation of ETB
receptors inhibits sodium and water transport [16]. ETB receptors also
mediate clearance of endothelin from the circulation [17], and this
effect appears to involve cross-talk with the ETA receptor, at least
under physiological conditions [18]. In the vasculature and the kidney,
via activation of its ETA receptors, endothelin has a basal (“tonic”)
vasoconstricting role; endothelins also contribute to myocardial
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tion, the latter of which is an important factor by which endothelin
facilitates the development of vascular disease in hypertension and
atherosclerosis (reviewed in Refs. [11,13]). In addition, endothelin
controls immune function and inﬂammation [19,20], glucose metab-
olism, and metabolic functions in adipose tissue and liver [13].
2. Proteinuric renal disease due to glomerulosclerosis
Chronic renal disease can be both cause and consequence of
chronically elevated arterial blood pressure. Other contributing
factors accelerating the development of renal disease that are
frequently coexisting with hypertension are diabetes due to obesity,
hyperinsulinemia, high cholesterol plasma levels, and aging [21].
Sclerosis of the glomerulus involves glomerular obsolence with
ﬁbrosis of the tuft and podocyte injury. Renal failure itself leads to
hypertension (secondary renal–parenchymal hypertension) and
aggravates coexisting risk factors such as dyslipidemia because of
increased loss of lipoproteins due to a defective glomerular ﬁltration
barrier and compensatory upregulation of hepatic lipoprotein
synthesis [22]. Between the early 1990s and 2002, the incidence of
chronic renal failure in the United States has almost doubled [23].
Numbers are still increasing, and similar developments have been
reported elsewhere in the world [24–26].
The main cause of deaths in patients with severe chronic renal
disease are cardiovascular complications such as myocardial infarc-
tion or stroke due to cerebrovascular disease [27–29]. Chronic renal
disease also represents a major economic challenge to health systems
worldwide as the health costs related to chronic renal disease have
quadrupled [23]. In view of the anticipated growth of the world
population from 6 to 9 billion within the next 40 years [30], the
economic burden related to chronic renal disease can be expected to
increase even further. Importantly, the prevalence of obesity in
Western countries such as Germany is highest among individuals
aged 50 to 70 years [31], an age group in which comorbidities such a
arterial hypertension, albuminuria, and diabetes are frequently
present [32,33].
3. Arterial hypertension
Treatment of arterial hypertension and the prevention of end-
organ damage associated with it remain a major task yet to be
accomplished in clinical medicine. In many patients suffering from
arterial hypertension, the disease is either insufﬁciently treated or
even undiagnosed [34,35], creating a substantial disease burden. The
major clinical complications related to arterial hypertension are myo-
cardial infarction, stroke, and renal disease [27,36], which form the
number one cause of mortality and disability in Western countries.
Many of the patients with so-called essential hypertension develop
the disease due to genetic predisposition [34,35]; however, an
increasing number of patients is being diagnosed with hypertension
due to secondary conditions such as obesity, renal failure, or meno-
pause [27,37–39]. Hypertension due to obesity, which is associated
with renal injury [40,41], is increasingly seen in school children
[39,42,43]. Other conditions such as Conn's disease or pheochromo-
cytoma represent only a small proportion of secondary causes of
hypertension [44].
Although hypertension often, over many years, goes unnoticed
without symptoms [34,35], chronic elevation of blood pressure leads
to a number of changes within the body, causing substantial organ
damage in the arterial wall, the myocardium, the kidney, the brain,
and the eyes, among others [45]. The most prominent feature of
arterial hypertension is an increased vascular resistance leading to
structural changes in the vascular wall [46]. Increased blood pressure
results in hypertrophy of the medial smooth muscle layer and causes
abnormal vasomotion promoting vasoconstriction [47]. Speciﬁcally,hypertension is associated with an attenuation of nitric oxide-
dependent vasodilation due to increased oxidative stress [48] and
an increased sensitivity to vasoconstrictors such as norepinephrine or
angiotensin II and, in particular, increased formation and activity of
endothelin-1 [49–51]. Despite continued advances in antihyperten-
sive therapy, many hypertensives with or without chronic kidney
disease are insufﬁciently treated or show little response to antihy-
pertensive treatment, even when treated with a combination of
several antihypertensive drugs [52]. Blood pressure in patients with
uncontrolled arterial “essential” hypertension – even under triple
antihypertensive therapy – is considered as “therapy-resistant
hypertension” [53,54]. Therapy-resistant hypertension is particularly
frequent in Blacks, Hispanics, patients with obesity, and post-
menopausal women [38,54,55]. It appears that salt sensitivity and
thus salt intake play an important role in the pathogenesis of resistant
hypertension [56]. Early on, endothelin was suspected to play a role in
arterial hypertension since surgical removal of an endothelin-
producing hemangioendothelioma resulted in normalization of
blood pressure in a hypertensive patient [57]. However, endothelial
cells are not the only cells producing endothelin; endothelin-1 is also
produced by vascular smooth muscle cells, renal mesangial cells,
glomerular podocytes, white blood cells, and others (reviewed in Ref.
[21]). Interestingly, endothelial cell-speciﬁc overexpression of
endothelin-1 causes vascular remodeling and abnormal changes in
function even independent of blood pressure [58], in line with the
pressure-independent effects of systemic endothelin-1 overexpres-
sion in other organs involved in cardiovascular homeostasis [59].
4. Renal disease and glomerulosclerosis
The kidney plays a central role in the regulation of arterial blood
pressure by controlling blood volume, release of vasoactive sub-
stances, and blood ﬂow [60]. Therefore, renal disease can be
considered an important secondary cause of hypertension [61]. Over
the past 20 years, research has generated robust evidence that
endothelin plays a central role in kidney function and renal disease
progression [21,22,60,62]. Endogenous renal endothelin controls
water and sodium excretion and acid–base balance and maintains
normal renal cell growth and tonic vasoconstriction (reviewed in Refs.
[63,64]). However, under disease conditions or in the presence of
conditions such as arterial hypertension or diabetes, endothelin
production and activity increase and thereby promote the develop-
ment of glomeruloslerosis [22,62]. Endothelin-dependent mechan-
isms contribute to proteinuria and glomerular injury and particularly
involve injury of glomerular podocytes (Fig. 1) and activation of
ﬁbrogenic pathways in mesangial cells (reviewed in Ref. [65]).
Endothelin directly promotes glomerular production of collagen and
ﬁbronectin [66]. Renal disease, hypertension, and diabetes develop
at a faster rate in Blacks than in other ethnic groups [55]. Black
individuals even if normotensive have higher risk for these diseases
than Caucasians and also carry a higher risk of developing hyperten-
sion [67]. Interestingly, circulating levels of ET-1 are much higher in
Blacks than in other ethnic groups [67], with Blacks being particularly
susceptible to development of hypertension [55]. The fact that
circulating ET-1 levels substantially fall upon successful antihyper-
tensive therapy in hypertensive Blacks points at a possible causal
involvement of the endothelin system in this disease [68].
5. Mechanisms of endothelin-dependent renal injury
A common denominator of all ﬁbro-proliferative diseases are
inﬂammatory responses in the diseased organ [69,70]. The increased
formation of pro-inﬂammatory and ﬁbrogenic peptides such as angio-
tensin II appears to play an essential role in this process [71–73]. Renal
endothelin also activates pathways that have been independently
associated with the physiopathology of hypertensive renal disease,
Fig. 1. Schematic representation of the actions and interactions of ET-1 (yellow) between the glomerular capillary basement membrane (GBM, red), the glomerular endothelial cells
(GEC, blue), the glomerular podocytes (grey), and the slit diaphragm (green). The ﬁgure is based on a concept of intracellular glomerular communication initially put forward by Kalluri
[94], and features signalingmechanisms (proposed by the author (1)–(7)) throughwhich ET-1 contributes to podocyte and glomerular injury. ET-1 is released from cells on both sides of
the GBM, namely glomerular endothelial cells (GEC) and podocytes. The newly formed ET-1 then interacts with different cellular components of the glomerular capillary. ET-1 released
from GEC then act on the GBM (1), with the slit diaphragm (2), or with the podocyte (3). ET-1 release and signaling may also occur in the reverse direction. Finally, ET-1 released from
podocytes may interact with the GBM and vice versa (4). Within the podocyte, ET-1 activates endothelin ETA receptors (ETA–R) and promotes glomerular injury and sclerosis through
MAPKs p38 and p44/p42 pathways (5); ET-1 also stimulates the growth promoter and cyclin-dependent kinase-inhibitor p21waf/cip1, and pro-inﬂammatoryNF-kappa B (6). ET-1 causes
disruption of the F-actin cytoskeleton (7) and promotes dysfunction of the slit diaphragm (green), via activation of the Rho-kinase and PI3-kinase pathways.
Fig. 2. Regulation of endothelin-1 peptide concentrations by angiotensin II in kidney
and arteries in vivo and the effects of endothelin receptor blockade in a model of
experimental hypertension. Shown are endothelin peptide levels (pg ET-1/g tissue wet
weight) in normotonsive WKY control rats (open bars), hypertensive angiotensin II-
infused rats (ﬁlled bars), and hypertensive angiotensin-II-infused rats concomitantly
treated with the ETA-selective endothelin receptor antagonist darusentan (hatched
bars). Systolic blood pressure was increased in angiotensin-II-infused rats (mean value:
190mm Hg) and reduced in angiotensin-II–darusentan-treated rats (mean value:
172mm Hg). ET-1 peptide levels were 19±2 pg/g in the kidney (left panel, n=5) and
44±8 pg/g n the aorta (right panel, n=7) of control animals. Angiotensin II treatment
increased ET-1 peptide levels about threefold in both kidney and arteries, which was
completely prevented by the ETA antagonist (n=5–7/group) despite that blood
pressure levels were still in the hypertensive range. *pb0.05 vs. control, †pb0.05 vs. Ang
II. Figure reproduced from reference [79] with permission of the publisher.
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inﬂammation [69,74]. Endothelin itself stimulates the formation of
angiotensin II by increasing the activity of angiotensin-converting
enzyme [75,76]. Because angiotensin AT1 receptor blockade inhibits
endothelin-1 production in vivo [77], and beneﬁcial effects of AT1
receptor blockade are independent of podocyte AT1 receptor
expression, as demonstrated by Matsusake et al. [78], it is well
possible that angiotensin-mediated renal and podocyte injury is
directly mediated via endothelin [79]. Interestingly, in experimental
obesity, ACE in the kidney becomes activated, which can be
completely prevented by ETA receptor antagonists [80], suggesting
angiotensin-converting enzyme (ACE)-inhibitor-like functions of
these drugs in physiopathologies such as obesity. Obesity-associated
glomerulopathy is characterized by focal–segmental glomerulo-
sclerosis (FSGS) and appears to be reversible following successful
weight loss [40,41]. On the other hand, angiotensin II, the main
effector peptide of the renin–angiotensin system, activates renal
endothelin production [79] by partly pressure-independent mechan-
isms (Fig. 2) and causes renal inﬂammation [71–73].
The direct or indirect trophic effects of endothelin promote
mesangial cell proliferation as well as hypertrophy of the glomerular
basement membrane (GBM) (Fig. 1). GBM hypertrophy is indirectly
mediated via injury of glomerular epithelial cells and an important
indicator of injury of the glomerulus [81,82]. Other important factors
that aggravate glomerular injury via endothelin are hyperglycemia,
salt (sodium)-sensitive hypertension (Fig. 3) [83,84], or high levels of
aldosterone (reviewed in Refs. [22,85]). It is possible if not likely that a
main common determinant of the detrimental changes mediated by
endothelin is inﬂammation, which plays a crucial role for glomerulo-
sclerosis, and can be inhibited by ETA receptor antagonists [19,20].
Such a notion would be also supported by the ﬁndings of a pressure-
independent, antiproteinuric effect of ETA receptor antagonists in
proliferative nephritis, which – like angiotensin-II-induced renal
injury [71–73] – is characterized by glomerular inﬂammation [86].
Indeed, Pollock's group has recently demonstrated using the ETA
receptor antagonist atrasentan that endothelin blockade indeed has
anti-inﬂammatory effects in the diabetic kidney [87], effects that have
also been suggested by transplantation studies [88]. Finally, dietary
protein intake may also aggravate renal injury in an endothelin-
dependent fashion as suggested byWesson and colleagues [89]. Taken
together, data from preclinical prevention studies and transgenic
animal models provide convincing evidence for a critical involvementof the endothelin pathway in the pathogenesis of proteinuria and
glomerulosclerosis likely in part due to its pro-inﬂammatory activity
[20]. This makes endothelin receptor antagonists promising candi-
dates for the clinical treatment of proteinuric renal disease [22,90,91].
6. Podocytes—glomerular gatekeepers and their regulation by
endothelin receptors
Podocytes are glomerular epithelial cells that regulate the protein
ﬁlter function of the glomerulus and its slit diaphragm [74,81,82]
(Fig. 1). Wiggins recently proposed podocytopathy as a general
element of all glomerular diseases and emphasized the need for
Fig. 3. Effects of hypertension induced by dietary salt and effects of endothelin receptor blockade on structural vascular and renal injury in a model of salt-sensitive hypertension
(Dahl hypertension). Histologic sections of the thoracic aorta (upper panels, A–C) or renal cortex (lower panels, D–F) are shown. Left panels (A, D) are from control animals on a low-
sodium diet, middle panels (B,E) are from animals kept on a high-sodium (4%) diet for 2 months, and right panels (C, F) are from animals on a high-sodium diet concomitantly
treated with the endothelin ETA receptor antagonist darusentan. Upper panels: representative aortic sections from the study animals (H&E, original magniﬁcation: 63×). Vascular
hypertrophy in hypertensive animals is associated with increased media thickness and intralamellar widening, which is inhibited by concomitant Darusentan treatment. Lower
panels: representative renal histology in Dahl salt-sensitive rats (periodic acid Schiff , original magniﬁcation ×100). Salt-induced hypertension induced severe glomerulosclerosis
(E) that was largely prevented by ETA antagonist darusentan (F). Figures reproduced from M. Barton, L.V. d'Uscio, S. Shaw, P. Meyer, P. Moreau, T.F. Lüscher. ETA receptor blockade
prevents increased tissue endothelin-1, vascular hypertrophy and endothelial dysfunction in salt-sensitive hypertension. Hypertension 31, 499–504, 1998. With permission of the
publisher and the American Heart Association, and from BartonM, Vos I, Shaw S, Boer P, d'Uscio LV, Grone HJ, Rabelink TJ, Lattmann T, Moreau P, Luscher TF. Dysfunctional renal nitric
oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and
glomerulosclerosis. J Am Soc Nephrol 2000; 11: 835-45, with permission of the publisher and the American Society of Nephrology.
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Podocytes contain endothelin binding sites, and human podocytes
express a fully functional endothelin system, including endothelin
receptors, prepro-endothelin-1, and endothelin-converting enzyme-1
[22,93]. The actin cytoskeleton is essential for podocyte function and
structural integrity [94]. Angiotensin II, which is a strong inductor or
renal inﬂammation [71–73] and of renal endothelin production in vivo
(Fig. 2), promotes podocyte actin cytoskeleton disruption and
albumin permeability and promotes podocyte apoptosis in vitro [22]
and in vivo [95]; virtually identical effects on podocyte actin
cytoskeleton disruption have been observed following exposure to
endothelin [96]. The ﬁrst observation that endothelin could be indeed
involved in the podocyte injury came from experiments in human
podocytes demonstrating that injury due to puromycin aminonucleo-
side, which causes glomerulosclerosis in vivo [97,98], can be
prevented by using different selective ETA receptor antagonists, BQ-
123 or darusentan, or by gene silencing of the ETA receptor [93].
Interestingly, protein loading of podocytes induces endothelin
formation and hence increases glomerular permselectivity for
proteins, an effect that is regulated in an ETA-dependent manner
(reviewed in Ref. [22]). Moreover, endothelin appears to be a crucial
mediator of podocyte injury as pretreatment with ETA receptor
antagonists prevents actin cytoskeleton disruption after in vitro injury
by puromycin aminonucleoside [93], with similar effects seen after
angiotensin AT1-angiotensin receptor antagonist treatment
(reviewed in Ref. [22]). Consequently, endothelin has been implicatedin renal injury due to excessive protein load for which ETA receptor-
dependent mechanisms have been described (reviewed in Ref. [22]).
7. Endothelin antagonist treatment in diabetic nephropathy:
preclinical data
Hyperglycemia as metabolic consequence of diabetes stimulates
endothelin production and is associated with activation of renal
growth factors and mesangial cell proliferation (reviewed in Ref.
[99]). Urinary endothelin excretion is increased in patients with
diabetic nephropathy or with primary focal–segmental glomerulo-
sclerosis (reviewed in Ref. [22]). Podocyte depletion is also present in
diabetic or diabetic-obese (db/db) obese rodents lacking the leptin
receptor (reviewed in Ref. [22]). A number of studies have
investigated the therapeutic potential of endothelin receptor antago-
nists for the treatment of diabetic nephropathy due to insulin-
dependent or type 2 diabetes (reviewed in Ref. [22]). Importantly,
obesity is often associated with diabetes and characterized by insulin
resistance with high circulating levels of insulin, which itself is a
potent stimulus of endothelin production in vitro and in vivo
[100,101]. Thus, high local tissue or circulating levels of insulin will
further increase endothelin production. A high glucose milieu seen in
prediabetes or diabetes also causes actin cytoskeleton disassembly in
podocytes (Fig. 1) as has been observed with angiotensin II and
endothelin-1, and podocyte depletion and apoptosis appear to require
ROS-dependent mechanisms (reviewed in Refs. [22,90]). While in the
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podocytes become shed in diabetic nephropathy [102,103]. Podocytes
shedding into the urine has also been observed in patients with FSGS
and with pre-ecclampsia [104,105]. Most recent work suggests a
causal role for endothelin in the shedding process as recombinant
endothelin triggers nephrin shedding from podocytes, an effect that
can be prevented by blocking ETA receptors [106]. This suggests the
possibility that hyperglycemia-induced renal injury contributes to
glomerular podocyte loss via activation of endothelin. The loss of
viable podocytes into the urine might provide a new and rather
sensitive marker of early glomerular injury [103]. Urinary loss of
podocytes has also been observed in diabetic rodents and in patients
with obesity-associated diabetes diagnosed with obesity-associated
glomerulopathy [107], which pathologically is characterized by focal–
segmental glomerulosclerosis (FSGS) [40,41]. Also in insulin-depen-
dent type-1 diabetes in experimental models such as non-obese
diabetic mice, which spontaneously develops autoimmune diabetes,
up-regulation of the podocyte protein nephrin is present even before
the development of diabetes [108]. This supports the hypothesis that
the podocyte becomes a target of diabetic injury already very early in
the course of the disease. Blockade of endothelin receptors delays the
onset of autoimmune diabetes [109], consistent with the known
immunomodulatory functions of endothelin [19,20].
A number of experimental prevention studies have shown an
involvement of endothelin in diabetic nephropathy; however, in
many studies, partial or even complete normalization of blood
pressure was observed [110–112]. Interestingly, in those studies
where little or no changes in blood pressure were observed, effects
of endothelin blockade also did not affect glomerular ﬁltration
rate. Studies by Hocher and coworkers have demonstrated that the
ETA receptor antagonist darusentan reduces proteinuria and glomer-
ulosclerosis in type 1 diabetes [113], results that are supported
by several studies from Amann's laboratory [110,111,114,115]. The
latter investigators found that in insulin-treated streptozotocin-
diabetic rats, darusentan was as effective as ACE inhibition in reduc-
ing glomerulosclerosis, while ACE inhibition showed greater effect
in reducing blood pressure, proteinuria, and glomerular volume
[110,115]. Nevertheless, only ETA receptor blockade using darusen-
tan, but not ACE inhibition, completely restored the number of
glomeruli per kidney and increased the number podocytes per
glomerulus, suggesting that endothelin blockade has unique and
speciﬁc glomeruloprotective effects [110]. Possible mechanisms
involved in regeneration have been most recently reported by
Moeller's group [116,117] and by Benigni's group [112], who
reported that podocytes are recruited from parietal glomerular
epithelial cells via migration onto the glomerular tuft and contribute
to re-structuring the capillary architecture, respectively. In a study by
Amann and colleagues, increased podocyte expression of endothelin
was observed in diabetic hypertensive animals [110]; darusentan, an
ETA receptor antagonist, reduced podocyte injury and proteinuria
despite negligible effects on arterial blood pressure [110]. Benigni's
group recently reported similar effects using the non-selective
compound avosentan as an endothelin antagonist [112]. In their
recent study, the investigators even found reversal of glomerulo-
sclerosis and proteinuria, and additive effects were noted in animals
already treated with an ACE inhibitor [112]. Avosentan improved
capillary architecture and reduced inﬂammation [112]. While it has
been recently proposed that anti-inﬂammatory and indirect antiox-
idant effects also contribute to the antiproteinuric and anti-sclerotic
effects of endothelin blockade in diabetes [19,20,87], it is currently
unclear whether and to what degree the ETB receptor is important
for the nephroprotective effects of endothelin blockade [118,119];
data from studies in diabetic renin-dependent hypertensive rats
indicate a lack of protective effect of the non-selective endothelin
antagonist bosentan [120]. In another study, however, using the
avosentan, an antagonist with low receptor selectivity, the investi-gators found that the nephroprotective effect of avosentan in
diabetic atherosclerotic mice was comparable to that of the ACE
inhibitor quinapril, an effect that was associated with a reduction in
atherosclerosis and inﬂammatory activation [121].
8. Endothelin antagonist therapy for hypertensive nephropathy:
preclinical data
Within a few years after the discovery of endothelin, Benigni et al.
reported reductions in proteinuria and glomerulosclerosis after
selective blockade of ETA receptors in a renal mass reduction rat
model of hypertensive nephropathy [122]. A role for endothelin in
renal disease was further supported by work by Hocher and
colleagues showing that systemic overexpression of the human
prepro-endothelin gene [123] causes glomerulosclerosis, even in the
absence for changes in blood pressure. Numerous preclinical studies
have since conﬁrmed the renoprotective effects and shown that
blockade of ETA receptors potently inhibit the growth-promoting
effects of endothelin in conditions such as hypertensive nephropathy
(Figs. 2 and 3), as well as largely normotensive conditions such as
diabetes, obesity, or aging (reviewed in Refs. [21,22,62,91]). Chat-
ziantoniou and colleagues reported reversal of vascular ﬁbrosis and
collagen deposition in a model of NO-deﬁcient hypertension after
endothelin blockade [124]. Experimental prevention studies with
only very few exceptions found renoprotective effects of ERA
treatment that were associated with a partial reduction in blood
pressure. Several forms of hypertension (angiotensin-II-dependent,
renin-dependent, salt-loaded renin-dependent; aldosterone-induced,
genetically salt-sensitive, DOCA-salt induced)were studied (reviewed
in Ref. [85]), and as long as ETA receptors were blocked, renoprotec-
tion was achieved [11] (Fig. 3). Work by Vanecková and colleagues
even indicates that endothelin blockade maintains its profound
antiproteinuric effects even in the presence of malignant hyperten-
sion and that ERA treatment was associated with a reduction in
podocyte injury [125]. The importance of these studies is due to the
fact that treatment was begun after hypertension had been estab-
lished and that beneﬁcial effects on podocytes were seen even in the
absence of glomerulosclerosis, i.e., at an early stage of renal disease.
Vanecková and colleagues also found that in hypertensive rats,
podocyte injury preceded proteinuria [125]. The selective antagonist
atrasentan but not the non-selective antagonist bosentan prevented
podocyte injury and substantially reduced proteinuria despite the fact
that animals were still markedly hypertensive [125]. Podocyte injury
before development of glomerulosclerosis was also observed in Dahl
hypertensive rats, which was sensitive to mineralocorticoid receptor
blockade [126]. Importantly, unlike endothelin blockade or mineral-
ocorticoid receptor blockade, antihypertensive treatment with hy-
dralazine had no effect on podocyte injury, again indicating that the
nephroprotective effects are speciﬁc and largely pressure-indepen-
dent [126]. This would again be supported by the development of
glomerulosclerosis in the absence of hypertension in experimental
animals that overexpress human endothelin [123] and by the
beneﬁcial effects of endothelin blockade in experimental diabetes
discussed above.
9. Endothelin antagonists for focal–segmental glomerulosclerosis:
preclinical data
Focal–segmental glomerulosclerosis has been termed a “podocyte
disease” [92,127,128], and only a limited number of therapies are
available [129]. The signaling mechanisms are complex; however, a
role for nephrin/PI3 kinase signaling has been recently identiﬁed
[130] (Fig. 1). We have previously investigated the effects of endo-
thelin receptor antagonism using darusentan, an ETA-selective drug,
on established focal–segmental glomerulosclerosis and proteinuria
in a model of aging [93]. In these studies, which were the ﬁrst
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renal disease by ERAs under normotensive conditions [93] and
without changes in blood pressure, we found that 4 weeks of
treatment with darusentan reversed not only proteinuria by about
50% but also glomerulosclerosis (Fig. 4). The reversal effect was
associated with reduced glomerular expression of MMP-9, a newly
identiﬁed marker of glomerulosclerosis-associated podocyte injury
[131]. The anti-sclerotic and antiproteinuric effects were alsoFig. 4. Histological sections and electron micrographs demonstrating reversal of establishe
receptors. Aged rats, which had spontaneously developed focal–segmental glomeruloscleros
mesangial matrix expansion and hypertrophy of podocytes with enlarged nuclei, promin
indicating podocyte injury and cell activation. (B) After treatment with the ETA receptor-s
matrix expansion and podocyte hypertrophy and activation are much milder due to partial h
electron micrographs of podocytes and glomerular basement membranes from untreated
basement membrane hypertrophy and podocyte injury and detachment are evident. (C)
membrane with podocyte detachment. Injury of podocytes is characterized by hypertrophy
autophagy [132], and diffuse effacement of foot processes (E). Darusentan treatment impro
capillary hypertrophy (D). The high-power micrograph shows podocyte recovery after darus
and disappearance of absorption droplets/vacuolar degeneration. Scale bar (A, B), 50 μm. F
Parekh, T. Traupe, M. Lange, T. Lattmann, M. Barton. Role of podocytes for the reversal o
Hypertension 2004; 44: 974–981. With permission of the publisher and the American Hearindependent of renal blood ﬂow and glomerular ﬁltration rate.
Electron microscopy studies revealed that treatment also reversed
podocyte injury, which was characterized by vacuolar degeneration
of podocyte cell bodies and foot process fusion (Fig. 4C) [93]. These
changes in the aging kidney, which were recently identiﬁed to be at
least in part mediated by podocyte autophagy (autophagy-related 5
gene) [132], were completely reversed after darusentan treatment
(Fig. 4D and F) [93], strongly suggesting that ERA treatment affectsd glomerulosclerosis and podocyte injury following pharmacological blockade of ETA
is, were treated with darusentan or placebo for 4 weeks. (A) In untreated rats, moderate
ent nucleoles, and an increased number of intracytoplasmatic vesicles are present,
elective antagonist darusentan, glomerular injury is markedly reduced, and mesangial
ealing of the previously injured glomerulus and podocytes. Representative transmission
(C, E) and darusentan-treated aged kidneys (D, F). In untreated animals, glomerular
High-power micrograph, demonstrating thickening of glomerular capillary basement
, inclusion of cytoplasmatic absorption droplets due to vacuolar degeneration involving
ved attachment of the podocyte to the basement membrane and reversal of glomerular
entan treatment. Endothelin blockade is associated with a reduction of podocyte injury
igures reproduced from J. Ortmann, K. Amann, R.P. Brandes, M. Kretzler, K. Münter, N.
f glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition.
t Association.
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normalization of the thickness of the previously hypertrophied
glomerular basement membrane (Fig. 4D and F), the thickness
of which is proportional to the degree of disease and which is
dependent on podocyte-derived matrix proteins [81] (Fig. 1). These
data were the ﬁrst demonstration that endothelin represents a
previously unidentiﬁed factor regulating the architecture of the
glomerular capillary [93]; this has been recently strengthened by
work from Benigni's laboratory reporting similar ﬁndings, albeit
using a different endothelin antagonist [112]. The mechanisms
involved in disease regression appear to involve changes in podocyte
function and structure (Fig. 5) as well as capillary restructuring/
angiogenesis, which has been shown to be involved in renal repair.
These effects possibly occur via signaling through VEGF-mediated
angiogenesis, which mediates its effects through NO and/or via
accelerated formation of neo-vessels. Since ETA receptor blockade not
only increases bioactivity of NO [133], a strong stimulus of
angiogenesis, the L-arginine/NO pathway is likely to play a role in
glomerular repair following endothelin blockade. Whether and to
what extent endothelin inhibition underlies the antiproteinuric
effects of drugs other that ET receptor antagonists is not fully
understood. However, recent work from Benigni's and Remuzzi's
groups suggests that endothelin antagonists indeed promote capil-
lary (re-)growth in a non-aging model [112] and that treatment with
antiproteinuric drugs actually leads to re-population of podocytes in
the aging kidney [134]. Currently, ACE inhibitors and ARBs are the
only antiproteinuric drugs in clinical use, although antiproteinuric
effects have also been described for other drugs and treatments,
including inhibitors of HMG CoA reductase (statins) and certain
calcium antagonists (reviewed in Refs. [22,135,136]). Established
glomerulosclerosis was also reversed following chronic NO deﬁcien-
cy (which is also a feature of aging [136,137]) and effects were
independent of blood pressure [138,139]. These experimental data
further support the notion that the renoprotective effects of
endothelin antagonists are likely to be mostly if not completely
independent of systemic hemodynamics and that these drugs
represent a promising way to interfere with and even reverse
established proteinuria and glomerulosclerosis [22,90].Fig. 5. Proposed concept of renal disease regression after inhibition of endothelin action thro
podocytes (dark green) and formation of ﬁbrotic, “sclerotic” tissue (yellow) resulting in prote
by ETA antagonist treatment if renal structural injury is less than severe. Disease regressi
podocytes (dark green) and reversal of hypertrophy of the basement membrane of the glom10. Current status of clinical studies in renal patients using
endothelin receptor antagonists
Currently, several drug companies are evaluating endothelin
receptor antagonists (ERAs) as a new treatment option in patients
with proteinuric renal disease. One of the side effects common to the
ERA class of drugs – which appears to be transient and responds well
to diuretic therapy – is the early formation of peripheral edema. The
mechanism underlying edema formation is still not clear and may be
particular to humans as it has not been reported to occur in animals. A
comprehensive review of completed clinical trials that were ongoing
at the time (2005) has been published [140]. The most recent
developments with regard to the use of ERAs in clinical studies in
renal patients have taken place only in the past 2 years and will
therefore be discussed here.
10.1. Atrasentan/ABT-627/Xinlay™ (Abbott)
Atrasentan is a non-sulfonamide carboxylic acid, ETA-selective
antagonist with high selectivity. The ﬁrst clinical evidence for
antiproteinuric activities of the new ERA class of drugs was presented
already a decade ago by Rabelink's group, who reported different
degrees of reversal of proteinuria in 10 patients with type 1 diabetes
treated with the ETA antagonist atrasentan for 12 weeks [141,142].
The effects were seen on top of standard RAAS blockade with an AT1
receptor antagonist or/and ACE inhibitor. In some of the patients
treatment also had blood pressure-lowering effects. This initial
observation of antiproteinuric effects and the underlying mechanisms
is now being investigated in a clinical trial in diabetic patients with
proteinuria that is being performed by Abbott Laboratories [143].
10.2. Avosentan/SPP 301Ro-67-0656 (Speedel/Novartis)
Avosentan is a sulfonamide-based ERA with low receptor
selectivity that was licensed from Roche to Speedel Pharmaceuticals
(now Novartis). Unlike as claimed by investigators who participated
in the Speedel clinical trials [144,145], avosentan does not have ETA
selectivity as compared with other ERAs, a notion also supported byugh blockade of endothelin ETA receptors. Left: glomerular renal injury with damage of
inuria (“injury”). Right: glomerulosclerosis and subsequent proteinuria can be reversed
on is accompanied by improvements of glomerular architecture and regeneration of
erular capillary (“regression”).
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Wenzel et al. found substantial reductions in albuminuria in 286
patients with type 2 diabetic nephropathy of moderate severity after
12 weeks of treatment with avosentan [144]. Avosentan, like
bosentan, belongs to the sulfonamide class of drugs, which are
contra-indicated in patients with impaired liver function. Interest-
ingly, avosentan treatment also had a cholesterol-lowering effect,
which was also seen in patients treated with atrasentan [141,142]. As
with atrasentan, the antiproteinuric effects were obtained on top of
standard antiproteinuric therapy with ACE inhibition/angiotensin
receptor blockade, indicating an additional and independent beneﬁ-
cial effect of endothelin inhibition. The ASCEND (Avosentan on
Doubling of Serum Creatinine, End-stage Renal Disease and Death in
Diabetic Nephropathy) phase III clinical trial was stopped due to
severe drug-related side effects, including severe heart failure and
deaths [145,147,148]. These patients, which had advanced renal
failure with average eGFRs of 33 ml/min, were followed for 3 and
6 months, and again substantial reductions in albuminuria were noted
that were similar at both doses used [145,148]. Treatment effects
were independent of systemic blood pressure, suggesting that the
structural effects of the ETA antagonist treatment on the kidney
predominate with regard to its antiproteinuric effects. It should be
pointed out that the average BMI of the study patients was above
30 kg/m2, that is, patients were obese and had advanced renal disease
[148]. Obesity represents an additional and thus aggravating risk
factor for glomerulosclerosis in these patients [149] and also leads to
fatty liver disease and hypertension; it remains currently unknown in
addition to the high doses of avosentan used to what degree the high
morbidity of the study patients has contributed to the outcomes of the
this study. Also, it is very likely – since no data are available on the
lowest effective dose – that a lower dose of the drug might have
reduced the rate of adverse events. After Speedel Pharmaceuticals was
taken over by Novartis in 2008, the fate of avosentan is unknown.
10.3. Bosentan/Ro 47-0203/Tracleer™ (Actelion)
The sulfonamide-based, non-selective endothelin receptor antag-
onist bosentan developed by Roche Pharmaceuticals and licensed to
Actelion is currently being investigated for the potential indication as
antiproteinuric treatment in a small clinical trial in patients with
diabetic nephropathy [150]. As with the studies conducted by Abbott
Laboratories and Speedel Pharmaceuticals, treatment is performed on
top of RAAS inhibition. Doses will be up-titrated and investigated in a
small number of 35 patients, the study duration will be 16 weeks, and
completion of the study is expected within the year 2010 [150].
10.4. Darusentan/LU135252 (Gilead Sciences)
Darusentan is a non-sulfonamide, propanoic acid ETA receptor
antagonist formerly developed by Knoll AG, Germany. Focal–segmen-
tal glomerulosclerosis is a feature of hypertensive nephropathy in
patients with hypertension [61,149,151], which is associated with
accelerated development of renal disease due to salt sensitivity or
obesity [149]. Though endothelin blockade has been investigated as a
novel means to interfere with clinical hypertension since the late
1990s (reviewed in Ref. [152]) and a strong role for endothelin in the
disease had been proposed [153], resistant hypertension had not been
speciﬁcally addressed in clinical studies. Blockade of ETA receptors
using darusentan has been recently shown to effectively reduce blood
pressure in a phase II dose-ﬁnding trial in patients with resistant
hypertension treated with two antihypertensive drugs and a diuretic
[154]. Whether darusentan treatment in humans also exerts any
effects on reversing proteinuria or glomerulosclerosis as demonstrat-
ed in animals studies [93,155] (Fig. 3) or whether it has an impact on
morbidity or mortality in such patients remains to be shown. In a
recently completed phase III clinical trial [156], darusentan wassuperior in reducing sitting systolic and diastolic blood pressure
compared with another antihypertensive drug and darusentan
treatment met several of the secondary endpoints (that included
changes in 24-h blood pressure, reaching blood pressure goal levels
after 14 weeks, and changes in estimated GFR). Importantly, at the
highest dose, darusentan treatment reduced urinary albumin excre-
tion in patients with renal disease by almost 60%. Yet Gilead Sciences
in December 2009 announced to discontinue the development of
darusentan for the treatment of resistant arterial hypertension and its
related complications [156].
10.5. Sitaxentan/TBC11251/Thelin™ (Pﬁzer)
Sitaxentan is a sulfonamide-based ETA receptor antagonist with
high receptor selectivity developed by Texas Biotechnology/Encysive,
which was acquired by Pﬁzer in early 2008. Sitaxentan has been
recently investigated in patients with proteinuric non-diabetic renal
disease of different etiologies, including focal–segmental glomerulo-
sclerois. Sitaxentan is currently being investigated in a small clinical
with 27 patients and a treatment duration of 6 weeks, and results will
be compared to the calcium-antagonist nifedipin [157]. Some of the
results have been published demonstrating that the antiproteinuric
effect of sitaxentan is also present in non-diabetic renal patients
[157,158].
11. What the future holds
There are convincing preclinical and clinical data suggesting that
endothelin receptor blockade could become a novel treatment
paradigm to interfere with and even reverse proteinuric renal disease
in patients. Endothelin receptor blockers appear to offer therapeutic
efﬁcacy to inhibit proteinuric renal disease even on top of currently
approved antiproteinuric medications (Fig. 5). Thus, this class of drugs
could represent an urgently needed next step in renal medicine for
the treatment of patients with chronic proteinuric renal disease [159].
As genetic factors related to the components of the endothelin system
could inﬂuence the susceptibility to develop proteinuria in diabetics,
further pharmacogenomic studies are warranted. An issue relevant to
therapy in humans will also be to determine whether ETA receptor
selectivity represents a therapeutic advantage over non-selective
compounds. This is particularly important since the selectivity of
certain compounds may not be sufﬁciently high enough to avoid
blockade of ETB receptors, which may be an important determinant of
drug-related side effects such as edema. Clinical investigators should
determine factors such as careful drug dosing to avoid toxicity effects
and should select patients carefully taking into account the co-
morbidities and avoiding treatment of those that are severely ill, as
learned from the ASCEND trial [22,145,148]. In addition, future basic
science studies should address whether and in which way the
antiproteinuric effect of ET receptor blockade are different from
those of ACEIs or ARBs. Also, an unsolved question is whether the
use of ERAs might perhaps be even superior to ACEIs or ARBs in
certain forms of renal disease. Finally, it remains to be shownwhether
receptor selectivity for the ETA receptor will translate into an
improved clinical outcome such as survival or need for renal
transplantation, and whether and how side affects seen in the early
phases of ERA treatment (i.e., peripheral edema) can be avoided or
controlled. Certain renal patient subgroups could have greater beneﬁt
from ERA treatment than others, also, effects and side effects are likely
to differ between the two main classes of ERAs, the sulfmonamide-
derived and the propanoic acid-derived ERA compounds [21]. There
is, however, reason to believe that 20 years after the discovery of
endothelin, the new ERA class of drugs could provide us with new
renal therapies that might allow us to halt or even reverse proteinuric
renal disease in patients [21,119,159] (Fig. 5).
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